CC
RLAY icon

Centiva Capital’s Relay Therapeutics RLAY Stock Holding History

Centiva Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,675
Closed -$105K – 2443
2024
Q1 		$105K Buy
+12,675
New +$124K ﹤0.01% 1600
2021
Q2 		– Sell
-18,593
Closed -$643K – 1593
2021
Q1 		$643K Buy
+18,593
New +$807K 0.02% 473

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Centiva Capital's RLAY Position: Q2 2024 in Review

Centiva Capital sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 12,675 shares — an estimated $105K sold.

Centiva Capital first reported a position in RLAY in Q1 2021 and held it in 2 quarters. The position peaked at $643K in Q1 2021. 179 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

  • Centiva Capital reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Centiva Capital sold 12,675 Relay Therapeutics shares in Q2 2024, an estimated $105K.
  • Centiva Capital first reported a position in Relay Therapeutics in Q1 2021 and held it in 2 quarters.
  • Centiva Capital's Relay Therapeutics position peaked at $643K in Q1 2021.
  • 179 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Centiva Capital's 13F filing for Q2 2024, filed 14 Aug 2024.